Sidley represented Sino Biopharmaceutical Limited in an option and license agreement with Boehringer Ingelheim covering six preclinical oncology programs involving antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). Under the agreement, Sino Biopharmaceutical will receive US$358 million in upfront and near-term payments and is eligible for up to US$7 billion in additional milestone payments, plus royalties on future product sales. Sino Biopharmaceutical will lead early development through global Phase I clinical trials, after which Boehringer Ingelheim may exercise options to obtain exclusive development and commercialization rights. The transaction marks the second oncology collaboration between the companies.
More information about the transaction is available here.
The Sidley team was led by Lila Hope (Technology and Life Sciences Transactions) and included Ruchun Ji (M&A); Jennifer Raab, Jean Qiu, Collin Marshall, and Yuhan Wu (Technology and Life Sciences Transactions); and Chen Yang (Food, Drug and Medical Device).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
